Key result
Early PCI after reperfusion is linked to a ~50% reduction in ischemic and bleeding events.
Why the study?
Early PCI has shown no benefit when performed early after thrombolysis alone, and its utility after thrombolysis combined with glycoprotein IIb/IIIa inhibition was examined.
Does early PCI after reteplase with or without abciximab improve clinical outcomes in patients with acute myocardial infarction?
Observational (n=485)
Does early PCI after reteplase with or without abciximab improve clinical outcomes in patients with acute myocardial infarction?
Early PCI facilitated by abciximab and reduced-dose reteplase appears safe and effective in acute myocardial infarction, reducing ischemic and bleeding events compared to no early PCI.
Answers are grounded in this paper and cite their sources.
May support early PCI after reperfusion in AMI; hypothesis-generating observational data requiring randomized confirmation.
OBJECTIVES: We examined the utility of early percutaneous coronary intervention (PCI) in a trial that encouraged its use after thrombolysis and glycoprotein IIb/IIIa inhibition for acute myocardial infarction (MI). BACKGROUND: Early PCI has shown no benefit when performed early after thrombolysis alone. METHODS: We studied 323 patients (61%) who underwent PCI with planned initial angiography, at a median 63 min after reperfusion therapy began. A blinded core laboratory reviewed cineangiograms. Ischemic events, bleeding, angiographic results, and clinical outcomes were compared between early PCI and no-PCI patients (n = 162), between patients with Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 or 1 before PCI versus flow grade 2 or 3, and among three treatment regimens. RESULTS: Early PCI patients showed a procedural success (<50% residual stenosis and TIMI flow grade 3) rate of 88% and a 30-day composite incidence of death, reinfarction, or urgent revascularization of 5.6%. These patients had fewer ischemic events and bleeding complications (15%) than did patients not undergoing early PCI (30%, p = 0.001). Early PCI was used more often in patients with initial TIMI flow grade 0 or 1 versus flow grade 2 or 3 (83% vs. 60%, p < 0.0001). Patients receiving abciximab with reduced-dose reteplase (5 U double bolus) showed an 86% incidence of TIMI grade 3 flow at approximately 90 min and a trend toward improved outcomes. CONCLUSIONS: In this analysis, early PCI facilitated by a combination of abciximab and reduced-dose reteplase was safe and effective. This approach has several advantages for acute MI patients, which should be confirmed in a dedicated, randomized trial.
No takes yet. Share an insight, caveat, or question.
Herrmann et al. (2000) conducted an observational in Acute myocardial infarction (n=485). Early percutaneous coronary intervention (PCI) vs. No early PCI was evaluated on Ischemic events and bleeding complications (p=0.001). Early PCI after reperfusion therapy for acute myocardial infarction was associated with fewer ischemic events and bleeding complications compared to no early PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: